234 related articles for article (PubMed ID: 25732247)
1. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.
Raetz EA; Cairo MS; Borowitz MJ; Lu X; Devidas M; Reid JM; Goldenberg DM; Wegener WA; Zeng H; Whitlock JA; Adamson PC; Hunger SP; Carroll WL
Pediatr Blood Cancer; 2015 Jul; 62(7):1171-5. PubMed ID: 25732247
[TBL] [Abstract][Full Text] [Related]
2. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.
Advani AS; McDonough S; Coutre S; Wood B; Radich J; Mims M; O'Donnell M; Elkins S; Becker M; Othus M; Appelbaum FR
Br J Haematol; 2014 May; 165(4):504-9. PubMed ID: 24579885
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.
Gaynon PS; Angiolillo AL; Carroll WL; Nachman JB; Trigg ME; Sather HN; Hunger SP; Devidas M;
Leukemia; 2010 Feb; 24(2):285-97. PubMed ID: 20016531
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.
Pui CH; Pei D; Sandlund JT; Ribeiro RC; Rubnitz JE; Raimondi SC; Onciu M; Campana D; Kun LE; Jeha S; Cheng C; Howard SC; Metzger ML; Bhojwani D; Downing JR; Evans WE; Relling MV
Leukemia; 2010 Feb; 24(2):371-82. PubMed ID: 20010620
[TBL] [Abstract][Full Text] [Related]
5. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia.
Enshaei A; O'Connor D; Bartram J; Hancock J; Harrison CJ; Hough R; Samarasinghe S; den Boer ML; Boer JM; de Groot-Kruseman HA; Marquart HV; Noren-Nystrom U; Schmiegelow K; Schwab C; Horstmann MA; Escherich G; Heyman M; Pieters R; Vora A; Moppett J; Moorman AV
Blood; 2020 Apr; 135(17):1438-1446. PubMed ID: 32315382
[TBL] [Abstract][Full Text] [Related]
6. Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group.
Elgarten CW; Thompson JC; Angiolillo A; Chen Z; Conway S; Devidas M; Gupta S; Kairalla JA; McNeer JL; O'Brien MM; Rabin KR; Rau RE; Rheingold SR; Wang C; Wood C; Raetz EA; Loh ML; Alexander S; Miller TP
Pediatr Blood Cancer; 2022 Nov; 69(11):e29937. PubMed ID: 36083863
[TBL] [Abstract][Full Text] [Related]
7. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.
Winter SS; Dunsmore KP; Devidas M; Eisenberg N; Asselin BL; Wood BL; Leonard Rn MS; Murphy J; Gastier-Foster JM; Carroll AJ; Heerema NA; Loh ML; Raetz EA; Winick NJ; Carroll WL; Hunger SP
Pediatr Blood Cancer; 2015 Jul; 62(7):1176-83. PubMed ID: 25755211
[TBL] [Abstract][Full Text] [Related]
8. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.
Borowitz MJ; Wood BL; Devidas M; Loh ML; Raetz EA; Salzer WL; Nachman JB; Carroll AJ; Heerema NA; Gastier-Foster JM; Willman CL; Dai Y; Winick NJ; Hunger SP; Carroll WL; Larsen E
Blood; 2015 Aug; 126(8):964-71. PubMed ID: 26124497
[TBL] [Abstract][Full Text] [Related]
10. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
[TBL] [Abstract][Full Text] [Related]
11. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.
Peters C; Schrappe M; von Stackelberg A; Schrauder A; Bader P; Ebell W; Lang P; Sykora KW; Schrum J; Kremens B; Ehlert K; Albert MH; Meisel R; Matthes-Martin S; Gungor T; Holter W; Strahm B; Gruhn B; Schulz A; Woessmann W; Poetschger U; Zimmermann M; Klingebiel T
J Clin Oncol; 2015 Apr; 33(11):1265-74. PubMed ID: 25753432
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Wayne AS; Shah NN; Bhojwani D; Silverman LB; Whitlock JA; Stetler-Stevenson M; Sun W; Liang M; Yang J; Kreitman RJ; Lanasa MC; Pastan I
Blood; 2017 Oct; 130(14):1620-1627. PubMed ID: 28983018
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).
Loh ML; Tasian SK; Rabin KR; Brown P; Magoon D; Reid JM; Chen X; Ahern CH; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2015 Oct; 62(10):1717-24. PubMed ID: 25976292
[TBL] [Abstract][Full Text] [Related]
15. Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives.
Franca R; Favretto D; Granzotto M; Decorti G; Rabusin M; Stocco G
Curr Med Chem; 2017; 24(11):1050-1065. PubMed ID: 28088906
[TBL] [Abstract][Full Text] [Related]
16. CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).
Tasian SK; Gardner RA
Ther Adv Hematol; 2015 Oct; 6(5):228-41. PubMed ID: 26425336
[TBL] [Abstract][Full Text] [Related]
17. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
Pulsipher MA; Carlson C; Langholz B; Wall DA; Schultz KR; Bunin N; Kirsch I; Gastier-Foster JM; Borowitz M; Desmarais C; Williamson D; Kalos M; Grupp SA
Blood; 2015 May; 125(22):3501-8. PubMed ID: 25862561
[TBL] [Abstract][Full Text] [Related]
18. Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.
Ohanian M; Kantarjian H; Guy D; Thomas D; Jabbour E; O'Brien S
Expert Opin Biol Ther; 2015 Apr; 15(4):601-11. PubMed ID: 25775418
[TBL] [Abstract][Full Text] [Related]
19. Ikaros and leukaemia.
Olsson L; Johansson B
Br J Haematol; 2015 May; 169(4):479-91. PubMed ID: 25753742
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
